...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Embargo
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Does anyone expect we may hear something positive comeout of this late breaking abstract for the phase 1 Zen 3694 trial, if the trial failed why would they start go on to the combo trial,  

 

Anyone think we may a good surprise NR before the late breaking abstract?

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply